Alerts

A shortage of Bicillin L-A 1.2 million unit prefilled syringes is anticipated from 20 December 2024 to 10 January 2025. A PBS-listed substitute product is available.

Pharmacists may dispense alternative brands or strengths without a new prescription.

The oral antihistamine promethazine hydrochloride, sold as Phenergan and other generic brands, should not be given to children under 6 years of age.

African Vigorous Max Strength poses a serious risk to your health and should not be taken.

We have tested a further 6 imported, unregistered ivermectin products and found they are counterfeit under the Therapeutic Goods Act 1989.

Ziyinzhuangyang tablets pose a serious risk to your health and should not be taken.

Metalyse is now available for use in all clinical settings.

Consumers and health professionals should be aware that counterfeit Ozempic-labelled pens have been imported into Australia. These pens may pose a serious health risk and should not be used. There are clear inconsistencies from the original product to look out for.

We have made a new Serious Scarcity Substitution Instrument to help manage the shortage and upcoming discontinuation of Ryzodeg 70/30 FlexTouch insulin.

The new KwikPen presentation of Mounjaro is now available but supply of all strengths of Mounjaro vials remains limited.

We have been advised that Novo Nordisk will gradually discontinue some of its earlier generation insulin products over the next 2 years.

Shortage resolved

We have become aware of an increasing number of cases of liver injury reported in scientific literature, by consumers who had taken products containing Garcinia gummi-gutta.

Pharmaceutical company Novo Nordisk has advised us that a new brand of semaglutide approved for chronic weight management, Wegovy, will be available in Australia from early August 2024.

Medicine shortage alert

Robust Extreme capsules pose a serious risk to your health and should not be taken.

Shortage resolved

The TGA has received reports of serious adverse events in infants and children who have been given compounded wind and colic preparations containing Atropa belladonna (belladonna).

Read our safety advisory about this ingredient's potential to cause severe allergic reactions including anaphylaxis.

Due to Oxynorm being reinstated in Australia and Ordine shortage extension

Current shortage of Vyvanse 20 mg and anticipated shortage of Vyvanse 60mg capsules.

The affected bi-level positive airway pressure (BiPAP) devices may stop providing therapy on an intermittent or permanent basis and the ‘Ventilator Inoperative’ alarm will sound.

Fluoxetine substitution instrument has been extended.

extension of SSSI

Pharmacists can now substitute one Orencia 125 mg product for the other